Alnylam Pharmaceuticals (ALNY) versus Prima BioMed (PBMD) Head to Head Contrast
Alnylam Pharmaceuticals (NASDAQ: ALNY) and Prima BioMed (NASDAQ:PBMD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.
Institutional & Insider Ownership
94.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Prima BioMed shares are owned by institutional investors. 4.3% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Alnylam Pharmaceuticals has a beta of 3.04, meaning that its share price is 204% more volatile than the S&P 500. Comparatively, Prima BioMed has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
Earnings and Valuation
This table compares Alnylam Pharmaceuticals and Prima BioMed’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Alnylam Pharmaceuticals||$66.00 million||163.30||-$436.51 million||($5.12)||-22.95|
|Prima BioMed||$3.31 million||13.19||-$6.24 million||N/A||N/A|
Prima BioMed has higher revenue, but lower earnings than Alnylam Pharmaceuticals.
This table compares Alnylam Pharmaceuticals and Prima BioMed’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations for Alnylam Pharmaceuticals and Prima BioMed, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Alnylam Pharmaceuticals presently has a consensus target price of $97.75, indicating a potential downside of 16.80%. Prima BioMed has a consensus target price of $7.00, indicating a potential upside of 278.17%. Given Prima BioMed’s stronger consensus rating and higher probable upside, analysts clearly believe Prima BioMed is more favorable than Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company’s lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).
Prima BioMed Company Profile
Prima BioMed Ltd is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.